Gold Nanoparticle CpG Conjugates for Lymphoma Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diffuse large B cell lymphoma (DLBCL) have limited effectiveness, with only 33% overall survival rate for high-risk patients, and existing immunotherapies like checkpoint inhibition and CAR-T therapy are not sufficient for all patients, necessitating innovative approaches for improved outcomes.
Innovation Solution
Development of immune conjugate nanoparticles that combine CpG motifs with gold nanoparticles for targeted immunotherapy and photothermal therapy, enhancing immune stimulation and apoptosis in lymphoma cells by delivering CpG motifs directly to lymphoid organs and tumor sites, using class B and C CpG oligodeoxynucleotides with spacers for improved stability and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard chemo-immunotherapy is used for DLBCL treatment, then treatment can be administered with existing protocols, but treatment effectiveness is limited with only 33% overall survival rate for high-risk patients
Solution Approach 1:
The patent combines gold nanoparticles with CpG oligodeoxynucleotides to create composite immune conjugate nanoparticles. This composite structure integrates the targeting and delivery capabilities of nanoparticles with the immunostimulatory properties of CpG, achieving enhanced therapeutic effectiveness (60-70% survival rate) while maintaining adaptability to different patient responses through selective activation of immune pathways.
Solution Approach 2:
The patent merges immunotherapy (CpG stimulation) with photothermal therapy (gold nanoparticle light absorption) into a single conjugate system. This combination allows simultaneous immune activation and direct tumor cell killing through photothermal effects, improving overall treatment effectiveness while providing versatile mechanisms to address variable patient responses.
2Reliability
If higher doses of CpG are administered to improve immune stimulation, then therapeutic effect increases, but toxicity increases
Solution Approach 1:
The gold nanoparticle acts as an intermediary carrier that delivers CpG oligodeoxynucleotides to target cells. This mediator enables effective immune stimulation at lower CpG doses by enhancing cellular uptake and retention, thereby reducing toxicity while maintaining therapeutic effect. The nanoparticle protects CpG from degradation and facilitates targeted delivery to lymphoid organs and tumor sites.
Solution Approach 2:
The patent changes the physical state and delivery parameters of CpG by conjugating it to gold nanoparticles. This transformation allows CpG to be delivered in a controlled manner with optimized dosage, achieving enhanced therapeutic effects at lower concentrations and reduced toxicity compared to free CpG administration.
3Reliability
If free CpG is administered systemically, then immune stimulation occurs, but distribution to lymphoid organs and tumor sites is insufficient
Solution Approach 1:
The gold nanoparticle serves as an intermediary delivery vehicle that transports CpG oligodeoxynucleotides to target sites. This mediator exploits the enhanced permeability and retention effect in tumors and the natural affinity of nanoparticles for lymphoid organs, achieving efficient targeted delivery and enhanced immune stimulation at the desired locations.
Solution Approach 2:
The patent segments the delivery system by using nanoparticles to carry CpG to specific anatomical regions (lymphoid organs and tumor sites) rather than relying on uniform systemic distribution. This segmentation enables localized accumulation and enhanced effectiveness at target sites while reducing off-target effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticles significantly reduce lymphoma cell viability, induce apoptosis, and increase cytokine and marker expression, demonstrating enhanced therapeutic effects compared to free CpGs, with potential for improved survival rates and reduced toxicity at lower CpG dosing.
Implementation Method 1
photothermal therapy
Implementation Method 2
gold nanoparticles... for photothermal therapy
Implementation Method 3
CpG motifs with gold nanoparticles for targeted immunotherapy... delivering CpG motifs directly to lymphoid organs and tumor sites
Data Source
AI summary
Disclosed herein are CpG conjugated nanoparticles for immunotherapy and photothermal therapy. The composition comprises class B CpG conjugated nanoparticles and/or a class C CpG conjugated nanoparticles where the class B CpG conjugated nanoparticles comprises a nanoparticle core and a class B CpG conjugated thereto and the class C CpG conjugated nanoparticles comprises a nanoparticle core and a class C CpG conjugated thereto.